title: Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
authors.forename: Ebru
authors.initials: E
authors.lastname: Koca
authors.forename: Ferda
authors.initials: F
authors.lastname: Sevimli
authors.forename: Deniz
authors.initials: D
authors.lastname: Cetiner
authors.forename: Ibrahim C
authors.initials: IC
authors.lastname: Haznedaroglu
authors.forename: Nilgun
authors.initials: N
authors.lastname: Sayinalp
authors.forename: Yahya
authors.initials: Y
authors.lastname: Büyükasik
authors.forename: Hakan
authors.initials: H
authors.lastname: Goker
authors.forename: Osman
authors.initials: O
authors.lastname: Ozcebe
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010879:Piperazines / Q000008:administration & dosage*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction; D017741:Survivors; D016312:Treatment Refusal; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D000068877:Imatinib Mesylate; D003520:Cyclophosphamide